{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-26-000058","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2026-07-28T20:05:51+00:00","discovered_at":"2026-07-28T20:07:00.639228+00:00","generated_at":"2026-07-28T20:07:07.013364+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NeoGenomics Q2 revenue up 11% to $202M; raises FY2026 guidance; settles DOJ matter","bullets":["Total revenue $202M (+11% YoY); clinical revenue $187M (+14%); NGS revenue +26%.","GAAP net income $2M (incl. $11M debt extinguishment gain) vs net loss $45M in Q2 2025.","Adjusted EBITDA $14M (+36% YoY); company raises full-year 2026 revenue and adjusted EBITDA guidance.","Completed $316M 0.75% convertible notes due 2032; repurchased $276M of existing 0.25% notes and $25M of common stock.","Finalized civil settlement with DOJ regarding consulting services; self-disclosed matter resolved."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-26-000058","json":"https://secwatch.observer/filing/0001077183-26-000058.json","markdown":"https://secwatch.observer/filing/0001077183-26-000058.md","text":"https://secwatch.observer/filing/0001077183-26-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/0001077183-26-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/neo-20260728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T20:07:07.013364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}